Last reviewed · How we verify
NCT05862051: RESOLUTE
RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
NA trial testing Local Ablative Therapy in Colorectal Cancer in 75 participants. Status unknown.
14 June 2024
Quick facts
| Lead sponsor | Australasian Gastro-Intestinal Trials Group |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 14 December 2021 |
| Primary completion | 14 June 2024 |
| Estimated completion | 14 June 2025 |
| Sites | 9 locations across Australia |
Drugs / interventions tested
- Local Ablative Therapy
- Standard first-line systemic treatment
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Oligometastatic Disease — all drugs for Oligometastatic Disease →
Sponsor
Australasian Gastro-Intestinal Trials Group — full company profile →
Who can join
18 and older, any sex, with Colorectal Cancer or Oligometastatic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic treatment for oligometastatic colorectal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05862051
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Australasian Gastro-Intestinal Trials Group trials
Trials by the same sponsor.
- NCT05042128 — The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastat · Phase 2 · active not recruiting
- NCT06290505 — A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study · Phase 2 · recruiting
- NCT04879368 — RegoNivo vs Standard of Care Chemotherapy in AGOC · Phase 3 · active not recruiting
- NCT03647839 — Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synerg · Phase 2 · completed
- NCT02365441 — A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of A · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05862051 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Australasian Gastro-Intestinal Trials Group
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05862051.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing